Cargando…
A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma.
The decarbazine analogue CB10-277 has been investigated for anti-tumour activity in a phase II study on malignant melanoma. Treatment was administered as a slow infusion of 12,000 mg m-2 over 24 h and repeated every 3 weeks. A total of 28 patients were entered into the study, of whom 23 were eligibl...
Autores principales: | Bleehen, N. M., Calvert, A. H., Lee, S. M., Harper, P., Kaye, S. B., Judson, I., Brampton, M. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1994
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033397/ https://www.ncbi.nlm.nih.gov/pubmed/7917939 |
Ejemplares similares
-
Phase I trial with pharmacokinetics of CB10-277 given by 24 hours continuous infusion.
por: Foster, B. J., et al.
Publicado: (1993) -
Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277.
por: Foster, B. J., et al.
Publicado: (1993) -
Phase II trials of fosquidone, (GR63178A), in colorectal, renal and non-small cell lung cancer. CRC Phase II Clinical Trials Committee.
por: Kaye, S. B., et al.
Publicado: (1992) -
Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer.
por: Kerr, D. J., et al.
Publicado: (1995) -
A phase I and pharmacokinetic study of didox administered by 36 hour infusion. The Cancer Research Campaign Phase I/II Clinical Trials Committee.
por: Carmichael, J., et al.
Publicado: (1990)